Janssen

The collaborators are each providing funding and samples, and plan to study about 100 patients with a subset of Castleman disease to identify biomarkers.

The purchase from Janssen of a liquid biopsy test for circulating tumor cells marks Menarini-Silicon's entry into the US diagnostics market.

The firm also announced that it plans to expand its RAS biomarker testing collaboration with Amgen in Europe.

Cellsearch is the only FDA-cleared circulating tumor cell test and is used to help manage patients with metastatic breast, prostate, and colorectal cancers.

The assay is the twelfth to be granted Emergency Use Authorization by the US Food and Drug Administration for Ebola testing. 

The companies will work to develop an affordable, portable, and easy-to-use HIV quantitative viral load test using Cue's Lab-In-A-Box MDx platform.

The companies will evaluate Diamir's technology as a potential companion diagnostic to certain Janssen neurodegenerative disease programs.

The assay runs on the company's fully automated PCR-based Idylla platform and detects various strains of the flu virus and respiratory syncytial virus.

Janssen will use data generated by Genometry for primary screening and library characterization, and to select drug candidates for clinical development.

Using a method that relied on Affymetrix arrays, researchers found that 38 patients in the trial had gene expression indicating they were in the ABC subtype.

Pages

Dog DNA testing finds that some purebreds might not truly be purebreds, Inside Edition reports.

Mary Beckerle has returned as director of the Huntsman Cancer Institute, according to ScienceInsider.

Smithsonian Magazine reports that environmental DNA sampling can be used to track elusive organisms.

In Genome Research this week: repetitive satellite DNA in the fruit fly, transcriptome map assembly pipeline, and more.